Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01920932 · ClinicalTrials.gov registry record · Phase 2
Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma
A Phase 2 study of Stage II Childhood Hodgkin Lymphoma and Stage III Childhood Hodgkin Lymphoma, sponsored by St. Jude Children's Research Hospital.
- Active
- Registry status
- Phase 2
- Development phase
- 77
- Enrollment target
- 6
- Study locations
NCT01920932: Active Phase 2 study of Stage II Childhood Hodgkin Lymphoma and Stage III Childhood Hodgkin Lymphoma, sponsored by St. Jude Children's Research Hospital.
NCT01920932 is a Phase 2 study of Stage II Childhood Hodgkin Lymphoma and Stage III Childhood Hodgkin Lymphoma that is active but no longer recruiting, run by St. Jude Children's Research Hospital. The registered enrollment target is 77 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (42% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01920932, a Phase 2 study of Stage II Childhood Hodgkin Lymphoma and Stage III Childhood Hodgkin Lymphoma, is active but no longer recruiting, sponsored by St. Jude Children's Research Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 77 participants
- Enrollment target
- 6
- Study locations
Study Summary
This pilot phase II trial studies how well giving brentuximab vedotin, combination chemotherapy, and radiation therapy works in treating younger patients with stage IIB, IIIB or IV Hodgkin lymphoma. Monoclonal antibodies, such as brentuximab vedotin, can block cancer growth in different ways. Some block the ability of cancer to grow and spread. Others find cancer cells and help kill them or carry cancer killing substances to them. Drugs used in chemotherapy, such as etoposide, prednisone, doxorubicin hydrochloride, cyclophosphamide, and dacarbazine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill cancer cells. Giving brentuximab vedotin with combination chemotherapy may kill more cancer cells and reduce the need for radiation therapy.
Primary Outcome
To determine the efficacy of 2 cycles of AEPA chemotherapy, the response rate for the first 32 evaluable participants enrolled was evaluated. If it shown efficacy (detect 20% increase complete rate with 80% power and 5% type I error compared with the proportion of historical control of HOD99 (NCT00145600) unfavorable risk patients had complete rate at week 8 of 17% (24/141), the response results will be reported in a national/international meeting and the study will continue to enroll for a tota
Conditions Studied
Interventions
- DRUG prednisone
- DRUG cyclophosphamide
- DRUG doxorubicin
- DRUG brentuximab vedotin
- DRUG etoposide
Study Locations (6)
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
- Dana-Farber Harvard Cancer Center - Boston
California
- Lucile Packard Children's Hospital Stanford University - Palo Alto
Illinois
- St. Jude Midwest Affiliate - Peoria
Maine
- Maine Children's Cancer Program (MCCP) - Scarborough
Tennessee
- St. Jude Children's Research Hospital - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2013-08-12 |
| Est. Completion | 2028-05 |
| Phase | Phase 2 |
What the registry record for NCT01920932 still lists
NCT01920932 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 77 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (42% lower).
The record links to 3 conditions, with Stage II Childhood Hodgkin Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which prednisone is the first listed.
NCT01920932 lists 6 locations in 5 states (Massachusetts, California, Illinois).
Frequently Asked Questions
What is clinical trial NCT01920932 about?
NCT01920932 is a clinical study titled "Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma". This pilot phase II trial studies how well giving brentuximab vedotin, combination chemotherapy, and radiation therapy works in treating younger patients with stage IIB, IIIB or IV Hodgkin lymphoma. Monoclonal antibodies, such as brentuximab vedotin, can block cancer growth in different ways. Some b...
What is the current status of trial NCT01920932?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 77 participants. The study started on 2013-08-12. Estimated completion is 2028-05.
What conditions does trial NCT01920932 study?
This clinical trial studies the following conditions: Stage II Childhood Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma.
What interventions are being tested in trial NCT01920932?
The interventions under investigation include: prednisone (DRUG), cyclophosphamide (DRUG), doxorubicin (DRUG), brentuximab vedotin (DRUG), etoposide (DRUG).
Who is sponsoring clinical trial NCT01920932?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01920932 being conducted?
This trial has 6 study locations across California, Illinois, Maine, Massachusetts, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01920932's enrollment target sits among peer trials
77 891st of 2000 higher than 1,108 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02127398 · 77 participants · Phase 2
Stool Transplants to Treat Refractory Clostridium Difficile Colitis
- NCT04159103 · 77 participants · Phase 1
Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia
- NCT04683003 · 77 participants · Phase 3
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
- NCT05004116 · 77 participants · Phase 1
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI